Partnology https://validator.w3.org/feed/docs/rss2.html Vertex to acquire Crinetics, Vera wins accelerated approval, Fate’s CAR-T shows early promise BridgeBio raises $1B, Genentech cuts 103 roles and signs $490M breat cancer deal with Astex Osanni Bio emerges from stealth with $190M Series B, Kartos acquired by Ipsen, Boundless Bio goes public Nura Bio raises $74M Series B, Biogen acquires RayThera, Iambic and Bayer AI collaboration Enliven raises ~$400M, Incyte aquires Vega, Beren secures $300M NewLimit raises $435M Series C, Nurix inks $2.3B deal with Roche, J&J acquires Firefly Bio Protuoso raises $9.5M Seed, Gilead cuts 51 roles, Vaccine Company acquired by Lilly cAMPfield launches with $180M, Edison Scientific and Genesis Molecular both partner with Incyte on AI drug development Kyverna files FDA approval, BioAge Labs pivots to inflammation, Aardvark hits major setback Artiva raises $300M, Perfuse acquired by Bayer Cyril De Colle, Cofounder & CSO at Neurogastrx Pranav Sharma, Founder and CEO of Xosomix Partnology Testimonials Leigh Hsu, Cofounder & CEO of Atticus Pharma Subhi Marwari, Founder & CEO of NeuraClick Alan Cohen, CMO at Arcturus Therapeutics Dolca Thomas, Co-founder & CEO of Neolaia Bio Profluent partners with Lilly in $2.25B deal, Candid acquires UCB, Protagonist $475M payout Ray raises $125M Series B, Soleno sells Neurocrine for $2.9B, Kyverna reports CAR-T breakthrough Rev Med prices $2B public raise, Terremoto raises $108M Series B, Kailera raises record $625M IPO Sidewinder raises $137M Series B, Gilead acquires Tubulis, Biotech VCs embrace risk again Infinimmune lands $838M Merck deal, Neurocrine acquires Soleno, Aurinia aquires Kezar Triangle raises $4M for AI, Blackstone $6.3B life sciences fund, Gilead $1.68B T-cell engager deal with Ouro R1 Therapeutics raises $77.5M Series A, Gossamer cuts 48%, Kali scores $180M deal with Sanofi Breakout Ventures $114M fund, Alto Neuro raise $120M, f5 Therapeutics shuts down Cellares raises $257M Series D, Eikon files for IPO, Tenpoint wins FDA approval Atrium launches with $270M, BioAtla lays off 70%, biopharma VC surges Faeth reverse merger with Sensei, Products peptide deal with Novartis, Vir partners with Astellas Evommune $125M private placement, Ultragenyx layoffs, Gilead licensing deal with Genhouse Angitia raises $130M Series D, Iambic AI drug discovery deal, SpyGlass $150M IPO debut Insights Mendra launches with $82M Series A, RAPT acquired by GSK, Janux signs deal with BMS Soley raises $200M Series C, Lux Capital raises $1.5B fund, Cartography signs $850M+ deal with Pfizer Samuel Collins, CMO at Mahzi Therapeutics Dynavax acquired by Sanofi, Ultragenyx late-stage failure, Crinetics posts strong sales Chai Discovery raises $130M Series B, Dren Bio lands $100M Sanofi deal, Arthrosi acquired by Sobi Immix raises $100M, Mirum acquires Bluejay, FDA moves to phase out primate testing Gary Li, Chief Strategy / Scientific Officer, Venture Advisor Day One acquired by Servier for $2.5B, Tenaya partners with Alnylam in $1.13B deal John Langowski, CSO at Micoy Therapeutics Protego raises $130M Series B, Cormorant targets $400M Fund Aspen Neuro raises $115M, Gilead acquires Sprint Bio, Cytokinetics nears FDA approval Solve raises $120M, Metagenomi cuts 25% of staff, Day One acquires Mersana Braveheart Bio raises $185M, A2 Bio CAR-T complete response in lung cancer, Rigel loses Eli Lilly partnership Ambros launches with $125M, Clavis forms $7.25B collaboration with Fosun, BioMarin acquires Amicus Genentech cuts 118 roles, Neurocrine signs $880M deal with TransThera, Evommune targets $150M IPO Chorom Pak, CEO of LynxBio Michael Mahler, CSO of Exagen John Fair, CEO of J3 Bioscience Partnology